About High affinity immunoglobulin epsilon receptor subunit alpha
High affinity immunoglobulin epsilon receptor subunit alpha (FCER1A) is a protein
from Homo sapiens identified by UniProt accession
P12319, 257 residues long.
MolForge cross-references it against 0 known binders and
176 disease associations.
Target properties
| Protein name | High affinity immunoglobulin epsilon receptor subunit alpha |
|---|
| UniProt accession | P12319 |
|---|
| Gene | FCER1A |
|---|
| Organism | Homo sapiens |
|---|
| Length | 257 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (176)
Diseases linked to this target (Open Targets).
- C-reactive protein measurement · score 0.45
- serum IgE measurement · score 0.39
- CCL2 measurement · score 0.28
- seasonal allergic rhinitis · score 0.20
- growth-regulated alpha protein measurement · score 0.20
- asthma · score 0.11
- viral disease · score 0.08
- experimental autoimmune encephalomyelitis · score 0.07
- self reported educational attainment · score 0.07
- mathematical ability · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P12319-F1 | alphafold | PREDICTED | 84.40 | — |
Amino-acid sequence (257 residues)
MAPAMESPTL LCVALLFFAP DGVLAVPQKP KVSLNPPWNR IFKGENVTLT CNGNNFFEVS STKWFHNGSL SEETNSSLNI VNAKFEDSGE YKCQHQQVNE SEPVYLEVFS DWLLLQASAE VVMEGQPLFL RCHGWRNWDV YKVIYYKDGE ALKYWYENHN ISITNATVED SGTYYCTGKV WQLDYESEPL NITVIKAPRE KYWLQFFIPL LVVILFAVDT GLFISTQQQV TFLLKIKRTR KGFRLLNPHP KPNPKNN
Explore High affinity immunoglobulin epsilon receptor subunit alpha with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets